Labcorp (NYSE:LH) EVP Kathryn Kyle Sells 92 Shares of Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Kathryn Kyle sold 92 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $26,329.48. Following the completion of the sale, the executive vice president directly owned 3,904 shares of the company’s stock, valued at approximately $1,117,285.76. This trade represents a 2.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Labcorp Price Performance

NYSE:LH traded up $4.75 during trading hours on Tuesday, reaching $289.14. 12,088 shares of the company traded hands, compared to its average volume of 670,102. Labcorp Holdings Inc. has a 1-year low of $241.81 and a 1-year high of $293.72. The firm’s 50-day moving average is $262.63 and its 200-day moving average is $266.45. The stock has a market cap of $23.71 billion, a P/E ratio of 25.58, a P/E/G ratio of 2.01 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the previous year, the business earned $3.84 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts expect that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Friday, May 29th were given a $0.72 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Institutional Trading of Labcorp

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hilltop National Bank lifted its position in shares of Labcorp by 161.0% during the 2nd quarter. Hilltop National Bank now owns 616 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 380 shares during the last quarter. CX Institutional lifted its position in shares of Labcorp by 16.3% in the 2nd quarter. CX Institutional now owns 1,455 shares of the medical research company’s stock valued at $407,000 after acquiring an additional 204 shares in the last quarter. Eastern Bank grew its position in Labcorp by 1,740.0% during the 2nd quarter. Eastern Bank now owns 276 shares of the medical research company’s stock worth $77,000 after purchasing an additional 261 shares in the last quarter. Western Wealth Management LLC purchased a new stake in shares of Labcorp in the first quarter valued at $130,000. Finally, Parallel Advisors LLC increased its holdings in shares of Labcorp by 11.6% in the 1st quarter. Parallel Advisors LLC now owns 4,540 shares of the medical research company’s stock valued at $1,212,000 after purchasing an additional 473 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Evercore reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Robert W. Baird set a $334.00 price target on shares of Labcorp in a report on Friday, May 1st. Finally, Wall Street Zen cut shares of Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and an average price target of $308.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.